Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae Infections

Introduction. The advent of ceftazidime-avibactam (CAZ-AVI)-resistant carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates has been steadily documented in recent years. We aimed to identify risk factors of CAZ-AVI-resistant CRKP infection and assess clinical outcomes of patients. Methods. The...

Full description

Saved in:
Bibliographic Details
Main Authors: Fatema Ahmed, Betsy Abraham, Nermin Kamal Saeed, Hasan Mohamed Naser, Kannan Sridharan
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Critical Care Research and Practice
Online Access:http://dx.doi.org/10.1155/2024/3427972
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849684427579326464
author Fatema Ahmed
Betsy Abraham
Nermin Kamal Saeed
Hasan Mohamed Naser
Kannan Sridharan
author_facet Fatema Ahmed
Betsy Abraham
Nermin Kamal Saeed
Hasan Mohamed Naser
Kannan Sridharan
author_sort Fatema Ahmed
collection DOAJ
description Introduction. The advent of ceftazidime-avibactam (CAZ-AVI)-resistant carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates has been steadily documented in recent years. We aimed to identify risk factors of CAZ-AVI-resistant CRKP infection and assess clinical outcomes of patients. Methods. The study retrospectively examined the clinical and microbiological data of patients with ceftazidime avibactam susceptible and ceftazidime avibactam-resistant Klebsiella pneumonia carbapenem-resistant enterobacteriaceae infection to identify risk factors, clinical features, and outcomes using multivariate logistic regression analysis. Results. A total of 152 patients with CRKP infection were enrolled in this study. Patients with CAZ-AVI-resistant CRKP isolates (20/34 = 58.8%) had prior exposure to carbapenems (p=0.003) and had more tracheostomies (16/34 = 47.1%) (p=0.001). Only 8/28 (28.6%) patients with CAZ-AVI susceptible CRKP isolates died amongst those administered ceftazidime-avibactam compared to 49/90 (54.4%) who did not receive the same (p=0.016). 1/9 (11.1%) patients with CAZ-AVI-resistant CRKP isolates who received colistin died compared to 13/25 (52%) who did not receive colistin (p=0.03). There was no association between presence of CAZ-AVI-resistant CRKP isolates and overall mortality (odds ratio: 0.7; 95% CI: 0.3, 1.6), and no independent predictors of risk factors to overall mortality in the group with CAZ-AVI-resistant CRKP isolates were noted. Conclusion. Early advent of CAZ-AVI resistance in CRE isolates highlights the dynamic necessity of routine CAZ-AVI resistance laboratory testing and antimicrobial stewardship programmes focusing on the utilization of all antibiotics. Consolidating the hospital infection control of tracheostomies may help to prevent CAZ resistance in CRKP. Colistin may aid in decreasing of mortality rates among patients with CAZ-AVI CRKP isolates.
format Article
id doaj-art-bb1ede1942f24f37bb1f1265f6c64f33
institution DOAJ
issn 2090-1313
language English
publishDate 2024-01-01
publisher Wiley
record_format Article
series Critical Care Research and Practice
spelling doaj-art-bb1ede1942f24f37bb1f1265f6c64f332025-08-20T03:23:27ZengWileyCritical Care Research and Practice2090-13132024-01-01202410.1155/2024/3427972Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae InfectionsFatema Ahmed0Betsy Abraham1Nermin Kamal Saeed2Hasan Mohamed Naser3Kannan Sridharan4Department of Intensive CareDepartment of Intensive CareDepartment of MicrobiologyDepartment of Intensive CareDepartment of Pharmacology and TherapeuticsIntroduction. The advent of ceftazidime-avibactam (CAZ-AVI)-resistant carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates has been steadily documented in recent years. We aimed to identify risk factors of CAZ-AVI-resistant CRKP infection and assess clinical outcomes of patients. Methods. The study retrospectively examined the clinical and microbiological data of patients with ceftazidime avibactam susceptible and ceftazidime avibactam-resistant Klebsiella pneumonia carbapenem-resistant enterobacteriaceae infection to identify risk factors, clinical features, and outcomes using multivariate logistic regression analysis. Results. A total of 152 patients with CRKP infection were enrolled in this study. Patients with CAZ-AVI-resistant CRKP isolates (20/34 = 58.8%) had prior exposure to carbapenems (p=0.003) and had more tracheostomies (16/34 = 47.1%) (p=0.001). Only 8/28 (28.6%) patients with CAZ-AVI susceptible CRKP isolates died amongst those administered ceftazidime-avibactam compared to 49/90 (54.4%) who did not receive the same (p=0.016). 1/9 (11.1%) patients with CAZ-AVI-resistant CRKP isolates who received colistin died compared to 13/25 (52%) who did not receive colistin (p=0.03). There was no association between presence of CAZ-AVI-resistant CRKP isolates and overall mortality (odds ratio: 0.7; 95% CI: 0.3, 1.6), and no independent predictors of risk factors to overall mortality in the group with CAZ-AVI-resistant CRKP isolates were noted. Conclusion. Early advent of CAZ-AVI resistance in CRE isolates highlights the dynamic necessity of routine CAZ-AVI resistance laboratory testing and antimicrobial stewardship programmes focusing on the utilization of all antibiotics. Consolidating the hospital infection control of tracheostomies may help to prevent CAZ resistance in CRKP. Colistin may aid in decreasing of mortality rates among patients with CAZ-AVI CRKP isolates.http://dx.doi.org/10.1155/2024/3427972
spellingShingle Fatema Ahmed
Betsy Abraham
Nermin Kamal Saeed
Hasan Mohamed Naser
Kannan Sridharan
Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae Infections
Critical Care Research and Practice
title Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae Infections
title_full Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae Infections
title_fullStr Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae Infections
title_full_unstemmed Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae Infections
title_short Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae Infections
title_sort retrospective tertiary care based cohort study on clinical characteristics and outcomes of ceftazidime avibactam resistant carbapenem resistant klebsiella pneumoniae infections
url http://dx.doi.org/10.1155/2024/3427972
work_keys_str_mv AT fatemaahmed retrospectivetertiarycarebasedcohortstudyonclinicalcharacteristicsandoutcomesofceftazidimeavibactamresistantcarbapenemresistantklebsiellapneumoniaeinfections
AT betsyabraham retrospectivetertiarycarebasedcohortstudyonclinicalcharacteristicsandoutcomesofceftazidimeavibactamresistantcarbapenemresistantklebsiellapneumoniaeinfections
AT nerminkamalsaeed retrospectivetertiarycarebasedcohortstudyonclinicalcharacteristicsandoutcomesofceftazidimeavibactamresistantcarbapenemresistantklebsiellapneumoniaeinfections
AT hasanmohamednaser retrospectivetertiarycarebasedcohortstudyonclinicalcharacteristicsandoutcomesofceftazidimeavibactamresistantcarbapenemresistantklebsiellapneumoniaeinfections
AT kannansridharan retrospectivetertiarycarebasedcohortstudyonclinicalcharacteristicsandoutcomesofceftazidimeavibactamresistantcarbapenemresistantklebsiellapneumoniaeinfections